Skip to main content

Table 1 Patient Demographics and Clinical Characteristics. Data are median (range) or n (%) unless otherwise indicated

From: Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

Characteristics

Renal cell carcinoma

N = 7 (28.0%)

Other tumor types

N = 18 (72.0%)

Patients

N = 25

Median Age, years (min-max)

53.10 (43.80–71.20)

62.55 (41.00–78.60)

61.90 (41.00–78.60)

Male

5

(71.4)

9

(50.0)

14

(56.0)

History of hypertension

3

(42.9)

6

(33.3)

9

(36.0)

Nephrectomy

6

(85.7)

1

(5.0)

7

(87.5)

Localization

 Cervix cancer

0

-

2

(11.1)

2

(8.1)

 Colorectal cancer

0

-

1

(5.6)

1

(5.6)

 Melanoma

0

-

4

(22.2)

4

(16.0)

 Pancreatic cancer

0

-

2

(11.1)

2

(8.1)

 Breast cancer

0

-

1

(5.6)

1

(5.6)

 Adrenocortical carcinoma

0

-

1

(5.6)

1

(5.6)

 Seminoma

0

-

1

(5.6)

1

(5.6)

 Lung cancer

0

-

1

(5.6)

1

(5.6)

 Other (head and neck, thyroid, bladder, mesothelioma)

0

-

5

(27.8)

5

(25.0)

M0 at diagnosis

5

(71.4)

13

(72.2)

18

(72.0)

Time between diagnosis and first metastases

 Mean (std)

11.86 (15–27)

21.73 (23–56)

18.85 (21–64)

 Median (min-max)

12.88 (−1.28–43.20)

16.29 (−0.39–80.06)

13.14 (−1.28–80.06)

 Missing

0

1

1

Time between diagnosis and first metastases

  ≤ 12 months

3

(42.9)

7

(41.2)

10

(41.7)

  > 12 months

4

(57.1)

10

(58.8)

14

(58.3)

 Missing

0

 

1

 

1

 

Number of metastatic sites

 1

5

(71.4)

12

(70.6)

17

(70.8)

  > 1

2

(28.6)

5

(29.4)

7

(29.2)

 Missing

0

 

1

 

1

 

 Median (min-max)

1 (1–1)

3 (1–6)

3 (1–6)

Number of prior therapy

 Chemotherapy

1

(14.3)

18

(100.0)

19

(76.0)

 Median number of previous chemotherapy (min-max)

1 (1–1)

3 (1–6)

3 (1–6)

 Bevacizumab

0

(0.0)

1

(5.6)

1

(5.3)

 Radiotherapy

3

(42.9)

13

(72.2)

16

(64.0)

Hemoglobin

  < 115 g/L (F), <130 g/L (M)

1

(14.3)

7

(38.9)

8

(32.0)

  ≥ 115 g/L (F), ≥130 g/L (M)

6

(85.7)

11

(61.1)

17

(68.0)

Serum creatinine (μmol/L)

 Median (min-max)

97.5 (84.0–127.0)

79.5 (49.0–127.0)

84.0 (49.0–127.0)

 Missing

1

0

1

AST (UI/L)

 Median (min-max)

17.0 (16.0–21.0)

33.0 (13.0–84.0)

24.0 (13.0–84.0)

 Missing

1

0

1

ALT (UI/L)

 Median (min-max)

21.0 (10.0–34.0)

28.0 (8.0–52.0)

26.0 (8.0–52.0)

 Missing

1

0

1

LDH > normal

2

(28.6)

10

(55.6)

12

(48.0)